949 reports of this reaction
4.1% of all FREMANEZUMAB VFRM reports
#3 most reported adverse reaction
MIGRAINE is the #3 most commonly reported adverse reaction for FREMANEZUMAB VFRM, manufactured by Teva Pharmaceuticals USA, Inc.. There are 949 FDA adverse event reports linking FREMANEZUMAB VFRM to MIGRAINE. This represents approximately 4.1% of all 22,887 adverse event reports for this drug.
Patients taking FREMANEZUMAB VFRM who experience migraine should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
MIGRAINE is moderately reported among FREMANEZUMAB VFRM users, representing a notable but not dominant share of adverse events.
In addition to migraine, the following adverse reactions have been reported for FREMANEZUMAB VFRM:
The following drugs have also been linked to migraine in FDA adverse event reports:
MIGRAINE has been reported as an adverse event in 949 FDA reports for FREMANEZUMAB VFRM. This does not prove causation, but indicates an association observed in post-market surveillance data.
MIGRAINE accounts for approximately 4.1% of all adverse event reports for FREMANEZUMAB VFRM, making it one of the most commonly reported side effect.
If you experience migraine while taking FREMANEZUMAB VFRM, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.